Komori
Financial results presentation4875MediciNova,Inc.Pharmaceuticals

Results Briefing Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026

For the cumulative second quarter of the fiscal year ending December 2026, operating revenue increased year on year, while operating loss and net loss narrowed, partly due to lower research and development expenses. Meanwhile, cash and cash equivalents declined from the end of the same period of the previous year, and progress was reported in multiple clinical trials, including completion of patient enrollment and preparations for data analysis.

Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
230249
¥ thousands (year-on-year improvement in operating loss)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationSecond quarter (interim period) of the fiscal year ending December 20264 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥103,732 thousand
Operating profit¥-864,190 thousand
Net income¥-787,591 thousand
Selling, general and administrative expenses¥549,655 thousand
Results for the three months of the current quarter
Operating revenue
¥73,680 thousand
Operating profit
¥-408,420 thousand
Net income
¥-371,928 thousand
Research and development expenses and patent expenses
¥165,407 thousand
General and administrative expenses
¥294,083 thousand
Service Cost of Revenue
¥22,610 thousand
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Operating revenue
Year-on-Year Change¥82,100 thousand
Research and development expenses and patent expenses
Year-on-Year Change¥-279,135 thousand
General and administrative expenses
Year-on-Year Change¥99,736 thousand
Service Cost of Revenue
Year-on-Year Change¥31,249 thousand
Operating Expenses
Year-on-Year Change¥-148,148 thousand
Operating profit
Year-on-Year Change¥230,249 thousand
Other Income (Expense)
Year-on-Year Change¥-1,852 thousand
Interest income
Year-on-Year Change¥-28,314 thousand
Net income for the current fiscal year
Year-on-Year Change¥200,082 thousand
New initiatives
  • Grant of a US patent for glioblastoma treatment using combination therapy with MN-166 and a PD-1 antibody
  • Plan for a new clinical trial involving patients with metastatic brain tumors
Key KPIsA metric the company considers important as a management benchmark.
  • COMBAT-ALS patient enrollment234 People
  • SEANOBI-ALS patient enrollment200 People
  • RECEDE patient enrollment64 People
  • OXTOX patient enrollment100 People
  • MN-001-NATG-202 patient enrollment40 People
  • ALS Patient Population in the United States16,000 people
  • Annual New ALS Diagnoses in the United States5,000 people
Market Size / Share
ALS Patient Population in the United States16,000 people
Annual New ALS Diagnoses in the United States5,000 people
Number of Cervical Spine Decompression Surgeries200,000 people
Annual New Glioblastoma Diagnoses in the United States13,000–14,000 people
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending December 2026
Net Sales¥103,732 thousand
Operating profit¥-864,190 thousand
Net income¥-787,591 thousand
Selling, general and administrative expenses¥549,655 thousand
Results for the three months of the current quarterOperating revenue ¥73,680 thousand / Operating profit ¥-408,420 thousand / Net income ¥-371,928 thousand / Research and development expenses and patent expenses ¥165,407 thousand / General and administrative expenses ¥294,083 thousand / Service Cost of Revenue ¥22,610 thousand
Breakdown of Factors Affecting the ChangeOperating revenue Year-on-Year Change ¥82,100 thousand / Research and development expenses and patent expenses Year-on-Year Change ¥-279,135 thousand / General and administrative expenses Year-on-Year Change ¥99,736 thousand / Service Cost of Revenue Year-on-Year Change ¥31,249 thousand / Operating Expenses Year-on-Year Change ¥-148,148 thousand / Operating profit Year-on-Year Change ¥230,249 thousand / Other Income (Expense) Year-on-Year Change ¥-1,852 thousand / Interest income Year-on-Year Change ¥-28,314 thousand / Net income for the current fiscal year Year-on-Year Change ¥200,082 thousand
Key KPIsIndicator name COMBAT-ALS patient enrollment / Value 234 People / Year on year against the same period last year Not disclosed, Indicator name SEANOBI-ALS patient enrollment / Value 200 People / Year on year against the same period last year Not disclosed, Indicator name RECEDE patient enrollment / Value 64 People / Year on year against the same period last year Not disclosed, Indicator name OXTOX patient enrollment / Value 100 People / Year on year against the same period last year Not disclosed, Indicator name MN-001-NATG-202 patient enrollment / Value 40 People / Year on year against the same period last year Not disclosed, Indicator name ALS Patient Population in the United States / Value 16,000 people / Year on year against the same period last year Not disclosed, Indicator name Annual New ALS Diagnoses in the United States / Value 5,000 people / Year on year against the same period last year Not disclosed
Market Size / ShareALS Patient Population in the United States 16,000 people / Annual New ALS Diagnoses in the United States 5,000 people / Number of Cervical Spine Decompression Surgeries 200,000 people / Annual New Glioblastoma Diagnoses in the United States 13,000–14,000 people
New initiativesGrant of a US patent for glioblastoma treatment using combination therapy with MN-166 and a PD-1 antibody, Plan for a new clinical trial involving patients with metastatic brain tumors
Items this document does not state (20)
Ordinary incomeGross Profit MarginOperating profit marginFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Operating revenue increased, while research and development expenses and patent expenses decreased year on year. General and administrative expenses and service cost of sales increased. For net income, lower interest income was a negative factor.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Results Briefing Materials for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 | MediciNova,Inc. (4875) timely disclosure | Komori